Comparative Pharmacology
Head-to-head clinical analysis: ATORVALIQ versus PITAVASTATIN CALCIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATORVALIQ versus PITAVASTATIN CALCIUM.
ATORVALIQ vs PITAVASTATIN CALCIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATORVALIQ is a combination of atorvastatin and amlodipine. Atorvastatin is an HMG-CoA reductase inhibitor that decreases cholesterol synthesis in the liver. Amlodipine is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle, causing vasodilation.
Competitive inhibitor of HMG-CoA reductase, reducing cholesterol synthesis in the liver and increasing LDL receptor expression.
10-80 mg orally once daily. Starting dose 10-20 mg. Max dose 80 mg.
1-4 mg orally once daily
None Documented
None Documented
The terminal elimination half-life of atorvastatin is approximately 14 hours; however, its active metabolites have a half-life of 20-30 hours, allowing for once-daily dosing.
The terminal elimination half-life is approximately 12 hours (range 9–16 hours), supporting once-daily dosing.
Atorvastatin is primarily eliminated via biliary/fecal excretion (approximately 70% as metabolites), with renal excretion accounting for less than 2% of the administered dose.
Approximately 79% of the dose is excreted in feces (as parent drug and metabolites) via biliary elimination, and about 15% is excreted in urine. Less than 2% is excreted unchanged in urine.
Category C
Category D/X
Statin
Statin